Characteristics of the studies included in the pooled analysis to evaluate the effects of single-agent erlotinib, single-agent gefitinib or chemotherapy in patients with EGFR mutation-positive NSCLC (studies not included in the original analysis are highlighted). This evidence concerns the gene EGFR and non-small cell lung carcinoma.